Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.
Children with phenylketonuric (PKU) are at risk for fractures. This study used a PKU murine model (PAH(enu-2)) to evaluate effects of moderate dietary protein restriction and elevated plasma phenylalanine concentration impact upon bone status. Fifty-four male weanling PKU and control mice were assigned to either an elemental phenylalanine (Phe)-restricted diet (treated) or Phe-unrestricted diet (untreated) with low or normal protein levels for 56 days. Untreated mice and control mice received equal amounts of dietary Phe; treated mice consumed prescribed dietary Phe to maintain plasma Phe concentrations between 120 and 480micromol/L. Plasma Phe, osteocalcin, and urine deoxypyridinoline (DPD)/creatinine were analysed at baseline and at days 28 and 56. Femur strength, bone mineral density (BMD) and bone mineral content (BMC) were analysed at day 56. Moderate protein restriction did not significantly affect bone status. Mean plasma Phe concentrations were significantly greater in untreated vs treated and control mice (p < 0.0001). Total body weight was significantly less in untreated vs control mice (p < 0.01). Mean femur weight was reduced in untreated mice vs both treated and control mice (p < 0.03). Untreated mice had smaller mean femur length than control mice (p < 0.002). Femur strength was greater in treated mice compared to control mice (p < 0.01) but not compared to untreated mice. No significant difference among groups was found in BMD and BMC. At day 56 there was a statistical trend (p < 0.056) towards higher urine DPD/creatinine excretion in untreated mice than in treated mice. Plasma Phe concentration was positively correlated with urine DPD/creatinine. These data suggested that hyperphenylalaninaemia may adversely affect bone status in PKU mice.
Yannicelli
S
S
Department of Human Nutrition and Food Management, College of Human Ecology, The Ohio State University, Columbus, USA.
Medeiros
D M
DM
D000818:Animals; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000175:diagnosis / Q000209:etiology; D004032:Diet; D004195:Disease Models, Animal; D005264:Femoral Fractures / Q000209:etiology; D005269:Femur / Q000473:pathology; D050723:Fractures, Bone / Q000209:etiology*; D008297:Male; D051379:Mice; D009929:Organ Size; D015675:Osteocalcin / Q000097:blood; D010649:Phenylalanine / Q000097:blood*; D010661:Phenylketonurias / Q000097:blood* / Q000150:complications / Q000178:diet therapy; D015430:Weight Gain
D015415:Biomarkers; D015675:Osteocalcin; D010649:Phenylalanine